Fig. 7. Depletion of ARF1 and ARF2 specifically inhibits convergent extension movements in activin-induced animal caps. (A) Animal caps cut at stage 8 from embryos injected with 50 ng control MO or 25 ng each of XFast-1 and XFast-3 MOs were either untreated (left panels) or treated with activin (20 ng/ml; right panels) until control embryos reached stage 13. (B) Expression of XFast-1 or XFast-3 rescues the inhibition of activin-induced convergent extension movements in XFast-1-depleted animal caps. Animal caps cut at stage 8 from embryos injected with 25 ng XFast-3 MO and 1 ng control GFP mRNA (a,b) or 25 ng XFast-1 MO with either 1 ng control GFP mRNA (c,d), Flag-tagged XFast-1 mRNA (e) or Flag-tagged XFast-3 mRNA (f) were either untreated (left panels) or treated with activin (40 ng/ml; right panels) until control embryos reached stage 13. Note that in a,c,d-f, some of the caps have stuck together.
